Informational nature
The information presented in this text is scientific and educational in nature. It is intended to describe molecular, cellular, and systemic biological processes. This text does not address specific pharmacological interventions or their clinical outcomes.
The content is based on peer-reviewed scientific literature and is intended to support a general understanding of physiological mechanisms.
Incretins are gut-derived hormones released in response to food intake that contribute to the regulation of metabolic processes. The primary incretins are GIP and GLP-1 [1,2].
GIP (glucose-dependent insulinotropic polypeptide) is a 42–amino acid peptide hormone synthesized by enteroendocrine K-cells of the small intestine in response to nutrient intake, particularly carbohydrates and fats [1,3].
The incretin effect describes the phenomenon whereby orally ingested glucose elicits a greater pancreatic secretory response than intravenously administered glucose at comparable blood glucose levels [1,2]. This effect is considered a key example of gut–pancreas signaling interactions.
Keywords: GIP hormone; glucose-dependent insulinotropic polypeptide; incretin system; GIP receptor (GIPR); incretin effect; cAMP signaling pathway; metabolic regulation
Historical background
The concept of incretins began to take shape in the early 20th century following observations that intestinal signals influence pancreatic function.
In the 1960s–1970s, a peptide initially termed “gastric inhibitory polypeptide” was identified based on its presumed role in gastric secretion [1,5].
Subsequent research demonstrated that its primary physiological role relates to the modulation of glucose-stimulated pancreatic secretion. Accordingly, it was renamed glucose-dependent insulinotropic polypeptide [1,2].
The identification of the GIP receptor in the 1990s, together with advances in understanding its structure and signaling pathways, thereby establishing GIP as a key component of incretin biology [2,4].
Contemporary research encompasses molecular, genetic, and systemic models aimed at investigating GIP signaling across multiple tissues [1,2,6].
Molecular structure and receptor
GIP exerts its effects via the GIP receptor (GIPR), a member of the class B G protein–coupled receptor (GPCR) family [2,4].
Receptor activation stimulates adenylate cyclase activity, resulting in increased intracellular cAMP concentrations and activation of downstream signaling pathways [2,4].
GIPR expression has been identified in:
- pancreatic β-cells,
- adipose tissue,
- specific regions of the central nervous system,
- other metabolically active tissues [1,2].
Key physiological mechanisms
1. Modulation of secretory processes
GIP is involved in the modulation of glucose-stimulated pancreatic secretory activity. This effect depends on metabolic context and glucose concentration [1,2].
Signaling pathways involve the cAMP/PKA system and changes in ion channel activity [2,4].
2. Regulatory aspects in α-cells
The effects of GIP on pancreatic α-cells are described as context-dependent and influenced by metabolic state. Different experimental models demonstrate variable response patterns [1,2].
3. Adipose tissue processes
In experimental models, GIP signaling has been associated with nutrient partitioning and lipid metabolism in adipose tissue [1,3].
Interpretation of these mechanisms in human physiology depends on the model and methodological framework applied.
4. Central nervous system aspects
GIPR has been identified in specific brain regions involved in the regulation of energy balance [2,6].
Model-based studies suggest potential roles in energy-related signaling; however, these findings should be interpreted with caution.
5. Bone metabolism associations
Some studies investigate the role of GIP in bone metabolism signaling; however, the available evidence remains limited and methodologically heterogeneous [1].
Methodological context
GIP biology is studied across multiple levels:
- the molecular level,
- cell culture models,
- animal models,
- human physiological observations [1–6].
Interpretation of results depends on study design, model selection, population characteristics, and statistical methodology [1,2].
Physiological hormonal signaling and data derived from experimental models are not directly equivalent; therefore, their interpretation requires careful contextual interpretation.
Discussion
GIP biology illustrates how the function of a single hormone can be analyzed across multiple levels—from molecular signaling to systemic metabolic integration.
Early research focused primarily on pancreatic secretory mechanisms, whereas subsequent studies revealed broader receptor expression and more complex inter-tissue interactions [1,2].
Context dependency is a critical interpretative factor. The effects of GIP depend on metabolic state, nutritional conditions, and concurrent hormonal signals. As a result, mechanistic findings derived from isolated systems do not necessarily reflect integrated physiological responses [1,2,4].
Different research models provide varying levels of insight, and the integration of such data requires methodological caution [1,3,6].
The incretin system functions as a dynamic and interconnected regulatory network in which analysis of a single signaling pathway may not adequately capture system-level responses.
Conclusions
- GIP is a physiological incretin involved in glucose regulation processes [1,2].
- Its receptor signaling involves cAMP-mediated mechanisms and is observed across multiple metabolically active tissues [2,4].
- Historical, molecular, and systemic studies indicate that GIP biology constitutes a complex and context-sensitive regulatory system, and its evaluation must be grounded in methodologically rigorous scientific evidence [1–6].
References
[1] Wolfe MM, et al. Glucose-Dependent Insulinotropic Polypeptide in Incretin Biology and Beyond. Endocrine Reviews. 2025.
https://academic.oup.com/edrv/article/46/4/479/8015721
[2] Müller TD, et al. Glucose-dependent insulinotropic polypeptide (GIP). Physiological Reviews. 2025.
https://pubmed.ncbi.nlm.nih.gov/40024571/
[3] Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007.
https://pubmed.ncbi.nlm.nih.gov/17198970/
[4] Mayo KE, et al. International Union of Pharmacology. The Glucagon Receptor Family. Pharmacological Reviews. 2003.
https://pubmed.ncbi.nlm.nih.gov/12615996/
[5] Brown JC, Dryburgh JR. A gastric inhibitory polypeptide. Canadian Journal of Biochemistry. 1971.
https://pubmed.ncbi.nlm.nih.gov/4936207/
[6] Campbell JE, Drucker DJ. Islet α cells and glucagon—critical regulators of energy homeostasis. Nature Reviews Endocrinology. 2015.
https://pubmed.ncbi.nlm.nih.gov/25936648/